arrow
P

Paul Nathan

Harefield Hospital
H指数:70
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare System

专科神经病学参与及对免疫检查点抑制剂相关神经毒性的影响:单一医疗体系中的经验

2025-12-090
OA
Uveal Melanoma UK National Guidelines: 2023 Update

脉络膜黑色素瘤英国国家指南:2023年更新

2025-08-050
PREAI
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific

接受T细胞受体-CD3双特异性抗体tebentafusp治疗期间肿瘤免疫景观的演变

2025-04-010
OAAI
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

皮肤黑色素瘤:ESMO 临床实践指南(用于诊断、治疗和随访)

2025-01-0111
PRE
Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers

血液T细胞适应性基因特征与ImmTAC双特异性T细胞衔接剂临床获益的关联

2024-09-010
PRE
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
2024-08-010
OA
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma

MEK抑制剂selumetinib单独或与紫杉醇联合治疗转移性葡萄膜黑色素瘤的三臂随机II期研究

2024-05-012
OAAI
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

一线转移性葡萄膜黑色素瘤中tebentafusp与nivolumab联合ipilimumab的总生存率: 倾向评分加权分析

2024-03-016
OA
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial

尼洛替尼治疗试剂盒驱动的晚期黑色素瘤: II期单臂NICAM试验的结果

2024-03-012
OAAI
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma

免疫检查点阻断治疗的晚期黑色素瘤的纵向肠道微生物组变化

2024-02-1617
OAAI
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

Tebentafusp治疗转移性葡萄膜黑色素瘤的三年总生存率

2023-12-1449
OA
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023
2023-10-0146
OAAI
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
2023-05-1622
PRE